From insight database () HEC89736PTSA.0.5 H2O is an oral highly selective PI3K inhibitor developed and synthesized by Dongsan Pharmaceuticals.
the project was first submitted for clinical application on 12 May 2020, approved for clinical approval on 11 July 2020 and first clinically publicized yesterday.
PI3K is one of the four sub-base of pi3K and an important member of the PI3K-AKT-mTOR signal path.
that PI3K is an important role in regulating adaptive immune system cells and innitive immune systems and is a potentially effective therapeutic target for a variety of immune diseases.
currently, there are no PI3K target inhibitors on the market, but 8 projects are in clinical development.
fastest-growing is Bayer's Kupanisi, which has started Phase III clinical programs in China, in addition to 5 Phase II clinical programs and 2 Phase I clinical programs.
involved enterprises including Zhengda Tianqing, Xinda Bio, Stone Pharmaceutical Group, Nanjing Sheng and so on.
from the Insight database () It is also worth noting that YY-20394 of Physiotherapy is also a PI3K inhibitor, which has previously been recognized as a breakthrough therapy for CDE and is currently in the process of being developed for Phase II clinical development.